Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: An add-on, double-blind, placebo-controlled study

International Clinical Psychopharmacology

Volumn 12, Issue 4, 1997, Pages 199-205

  Hayashi, T ^a   Yokota, N ^b   Takahashi, T ^c   Tawara, Y ^b   Nishikawa, T ^d   Yano, T ^c   Furutani, M ^a   Fujikawa, T ^b   Horiguchi, J ^b   Yamawaki, S ^b  

^a Hiroshima Seiyoin Mental Hospital   (Japan)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^c Koseiren Yoshida General Hospital   (Japan)

^d Seiwakai Nishikawa Hospital   (Japan)

Author keywords

Antidepressants; Mianserin; Negative symptoms; Schizophrenia; Serotonin; Tardive dyskinesia; Trazodone

Indexed keywords

MIANSERIN; SEROTONIN 2 ANTAGONIST; TRAZODONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; VERTIGO;

EID: 9844253332     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199707000-00003     Document Type: Article

References (55)

1. Albanese A, Rossi P and Altavista MC (1988) Can trazodone induce parkinsonism? Clinical Neuropharmacology, 11, 180-182.
2. Baumann PA and Maitre L (1977) Blockade of presynaptic α-receptors and of amine uptake in the rat brain by the antidepressant mianserin. Naunyn-Schmiedeberg's Archives of Pharmacology, 300, 31-37.
3. Bersani G, Grispini A and Marini S (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Current Therapeutic Research, 40, 492-499.
4. Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology, 91, 104-108.
5. Casey DE (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in non-human primates. Psychopharmacology, 112, S55-S59.
6. Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C and Scupicchio P (1994) Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hospital and Community Psychiatry, 45, 1220-1223.
7. Demuth GW, Breslow RE and Drescher J (1985) The elicitation of a movement disorder by trazodone: case report. Journal of Clinical Psychiatry, 46, 535-536.
8. Deutsch M, Ban TA and Lehmann HE (1977) A standard-controlled clinical study with trazodone in schizophrenic patients. Psychopharmacology Bulletin, 13, 13-14.
9. Duinkerke SJ, Botter PA, Jansen AAI, Van Dongen PAM, Van Haaften AJ, Boom AJ, Van Laarhoven JHM and Busard HLSM (1993) Ritanserin, a selective 5-HT2/lc antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. British Journal of Psychiatry, 163, 451-455.
10. El-Awar M, Freedman M, Seeman P, Goldenberg L, Little J and Solomon P (1987) Response of tardive dyskinesia and L-dopa-induced dyskinesia to antidepressants. The Canadian Journal of Neurological Sciences, 14, 629-631.
11. Garattini S (1974) Biochemical studies with trazodone: a new psychoactive drug. In: Trazodone. Vol. 9 Mode and Problem of Pharmacopsychiatry. (Eds TA Ban and B Silvestrini), pp. 29-46. Karger, Basel.
12. Garattini S, deGaetano G, Samanin R, Bernasconi S and Roncaglioni MC (1976) Effect of trazodone on serotonin in the brain and platelets of the rat. Biochemical Pharmacology, 25, 13-16.
13. Gelders YG (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. British Journal of Psychiatry, 155 Suppl 5, 33-36.
14. Gofff DC, Brotman AW, Waites M and McCormick S (1990) Trial of fluoxetine added on neuroleptic for treatment-resistant schizophrenic patients. American Journal of Psychiatry, 147, 492-494.
15. Haria M, Fitton A and McTavish D (1994) Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs & Aging, 4, 331-355.
16. Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N and Tanaka C (1993) Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology, 112, S35-S39.
17. Hayashi T, Yamawaki S, Nishikawa T and Jeste DV (1995). Usage and side effects of neuroleptics in elderly Japanese patients. American Journal of Geriatric Psychiatry, 3, 308-316.
18. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL and McAdams LA (1995) Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52, 756-765.
19. Jeste DV and Wyatt RJ (1982) Understanding and treating tardive dyskinesia. Guilford Press, New York.
20. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF and Kleinman JE (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenia. Neuropsychopharmacology, 8, 315-336.
21. Kahn RS, Davidson M, Knott P, Stern RG, Apter S and Davis KL (1993a) Fluid monoamine metabolite concentrations in schizophrenia: serotonin-dopamine interactions as a target for treatment. Archives of General Psychiatry, 50, 599-605.
22. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S and Davis KL (1993b) Serotonin function and treatment response to clozapine in schizophrenic patients. American Journal of Psychiatry, 150, 1337-1342.
23. Kahn RS and Davidson M (1993) Serotonin receptor responsivity in schizophrenia. International Clinical Psychopharmacology, 8 Suppl 2, 47-51.
24. Kahn RS and Weltzer S (1991) m-Chlorophenylpiperazine as a probe of serotonin receptors: a review. Biological Psychiatry, 30, 1139-1166.
25. Kapur S and Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. American' Journal of Psychiatry, 153, 466-476.
26. King DJ (1990) The effect of neuroleptics on cognitive and psychomotor function. British Journal of Psychiatry, 157, 799-811.
27. Klieser E and Lehmann E (1989) Experimental examination of trazodone. Clinical Neuropharmacology, 12 (Suppl 1), 18-24.
28. Kramer S, Marcus DJ, DiFerdinando J and Dewey D (1986) Atypical acute dystonia associated with trazodone treatment. Journal of Clinical Psychopharmacology, 6, 117-118.
29. Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, Litle P, Schmidt R and Kimes I (1989) Antidepressants in "depressed" schizophrenic inpatients. Archives of General Psychiatry, 46, 922-928.
30. Kuniyoshi M, Nakamura J, Miura C and Inanaga K (1994) Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18, 339-346.
31. Lu RB, Ko HC, Lin WL, Lin YT and Ho SL (1989) CSF neurochemical study of tardive dyskinesia. Biological Psychiatry, 25, 717-724.
32. Meltzer HY, Matsubara S and Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251, 238-246.
33. Mizuki Y, Kajimura N, Inami T, Suetsugi M, Kai S, Kaneyuki H and Yamada M (1990) Effect of mianserin on negative symptoms in schizophrenia. International Clinical Psychopharmacology, 5, 83-95.
34. Nishikawa T, Kaneda W, Uegaki A, Koga I, Uchida Y and Tanaka M (1992) Respiratory dyskinesia: a variety of clinical forms differentially diagnosed by using spirograph. Clinical Neuropharmacology, 15, 315-321.
35. Ohuoha DC, Hyde TM and Kleinman JE (1993) The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology, 112, S5-S15.
36. Overall JE and Rhodes JV (1982) Refinement of phenomenologic classification in clinical psychopharmacological research. Psychopharmacology, 77, 24-30.
37. Patel HC, Bruza D and Teragani V (1988) Myoclonus with trazodone. Journal of Clinical Psychopharmacology, 8, 152-152.
38. Plasky P (1991) Antidepressant usage in schizophrenia. Schizophrenia Bulletin, 17, 649-657.
39. Prusoff VA, Williams DA and Weissman MM (1979) Treatment of secondary depression in schizophrenia. Archives of General Psychiatry, 36, 569-575.
40. Raskind MA and Risse SC (1986). Antipsychotic drugs and elderly. Journal of Clinical Psychiatry, 47, 17-22.
41. Reyntjens A, Gelders YG and Hoppenbrouwers MLJA (1986) Thymostenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Research, 8, 205-211.
42. Richelson E (1982) Pharmacology of antidepressants in use in the United State. Clinical Psychiatry, 43, 4-11.
43. Salzman C (1987) Treatment of the elderly agitated patient. Journal of Clinical Psychiatry, 48 Suppl, 19-22.
44. Sandyk R (1989) The relationship of serotonin metabolism and melatonin secretion to the pathophysiology of tardive dyskinesia. Internationaljournal of Neuroscience, 48, 133-136.
45. Schmidt CJ, Kenne JH, Carr AA, Fadayel GM, Humphreys TM, Kettler HJ, McCloskey TC, Padich RA, Taylor VL and Sorensen SM (1993) Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity. International Clinical Psychopharmacology, 8 Suppl 2, 25-32.
46. Snow BJ and Calne DB (1992) The etiology of Parkinson's disease. In: Movement Disorders in Neurology and Psychiatry (Eds AB Joseph and RR Young), pp. 230-233. Blackwell Scientific Publications, Boston.
47. Stefanini E, Fadda F, Porceddu ML and Gessa GL (1976) Effect of trazodone on brain dopamine metabolism. Journal of Pharmacy and Pharmacology, 28, 925-926.
48. Sunderland T (1992) Neurotransmission in the aging central nervous system. In: Clinical Geriatric Psychopharmacology, 2nd edn (Ed. C Salzman), pp. 45-62. Williams & Wilkins, Baltimore.
49. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA and Murphy DL (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose-response study. Archives of General Psychiatry, 44, 418-426.
50. Tune LE and Coyle JT (1981) Acute extrapyramidal side effects: serum level of neuroleptics and anticholinergics. Psychopharmacology (Berlin), 95, 9-15.
51. Tune LE, Steele C and Cooper T (1991) Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatry Clinics of North America, 14, 353-373.
52. Van Putten T, Marder SR and Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754-758.
53. Wander TJ, Nelson A, Okazaki H and Richelson E (1986) Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. European Journal of Pharmacology, 132, 115-121.
54. Wolkowitz OM, Pickar D and Doran AR (1986) Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. American Journal of Psychiatry, 143, 85-87.
55. Wragg JM and Jeste DV (1988) Neuroleptics and alternative treatments: management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatry Clinics of North America, 11, 195-214.